@article{JTD29309,
author = {Taiki Hakozaki and Yusuke Okuma},
title = {Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {7},
year = {2019},
keywords = {},
abstract = {Osimertinib (AZD9291, Tagrisso™), a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has brought about rapid transformative changes to the treatment of EGFR-mutation-positive advanced non-small cell lung cancer (NSCLC). After acquiring resistance to first- or second-generation EGFR-TKIs, osimertinib showed greater efficacy than the combination of pemetrexed and platinum-based chemotherapy in patients with the exon 20 T790M resistance mutation in the AURA3 trial (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/29309}
}